These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 33886614)
21. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. Chandra A; Gurjar V; Qamar I; Singh N J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970 [TBL] [Abstract][Full Text] [Related]
26. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Peralta-Garcia A; Torrens-Fontanals M; Stepniewski TM; Grau-Expósito J; Perea D; Ayinampudi V; Waldhoer M; Zimmermann M; Buzón MJ; Genescà M; Selent J Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948390 [TBL] [Abstract][Full Text] [Related]
27. Identification of Persuasive Antiviral Natural Compounds for COVID-19 by Targeting Endoribonuclease NSP15: A Structural-Bioinformatics Approach. Saeed M; Saeed A; Alam MJ; Alreshidi M Molecules; 2020 Dec; 25(23):. PubMed ID: 33271751 [TBL] [Abstract][Full Text] [Related]
28. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
29. Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach. Motwalli O; Alazmi M J Mol Model; 2021 May; 27(6):160. PubMed ID: 33963942 [TBL] [Abstract][Full Text] [Related]
30. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Kumar S; Kashyap P; Chowdhury S; Kumar S; Panwar A; Kumar A Phytomedicine; 2021 May; 85():153317. PubMed ID: 32943302 [TBL] [Abstract][Full Text] [Related]
31. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Touret F; Gilles M; Barral K; Nougairède A; van Helden J; Decroly E; de Lamballerie X; Coutard B Sci Rep; 2020 Aug; 10(1):13093. PubMed ID: 32753646 [TBL] [Abstract][Full Text] [Related]
32. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D Cells; 2021 Dec; 11(1):. PubMed ID: 35011614 [TBL] [Abstract][Full Text] [Related]
33. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527 [TBL] [Abstract][Full Text] [Related]
34. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19. Perveen S; Khalili Yazdi A; Devkota K; Li F; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Vedadi M SLAS Discov; 2021 Jun; 26(5):620-627. PubMed ID: 33423577 [TBL] [Abstract][Full Text] [Related]
35. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of the hexamerization of SARS-CoV-2 endoribonuclease and modeling of RNA structures bound to the hexamer. Tran DP; Taira Y; Ogawa T; Misu R; Miyazawa Y; Kitao A Sci Rep; 2022 Mar; 12(1):3860. PubMed ID: 35264667 [TBL] [Abstract][Full Text] [Related]
37. What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen? Edwards A J Chem Inf Model; 2020 Dec; 60(12):5727-5729. PubMed ID: 32914973 [TBL] [Abstract][Full Text] [Related]
38. High throughput screening for SARS-CoV-2 helicase inhibitors. Otsuka Y; Kim E; Krueger A; Shumate J; Wang C; Bdiri B; Ullah S; Park H; Scampavia L; Bannister TD; Chung D; Spicer TP SLAS Discov; 2024 Sep; 29(6):100180. PubMed ID: 39173831 [TBL] [Abstract][Full Text] [Related]
39. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT mBio; 2021 Jan; 12(1):. PubMed ID: 33468703 [TBL] [Abstract][Full Text] [Related]
40. Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15. Shalayel MH; Al-Mazaideh GM; Aladaileh SH; Al-Swailmi FK; Al-Thiabat MG Pak J Pharm Sci; 2020 Sep; 33(5):2179-2186. PubMed ID: 33824127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]